# Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX

> **NCT01396707** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 55 (actual)

## Conditions studied

- Metastatic or Recurrent Gastric Adenocarcinoma
- Her-2 Positive Gastric Cancer

## Interventions

- **DRUG:** Herceptin+XELOX

## Key facts

- **NCT ID:** NCT01396707
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2018-11
- **Final completion:** 2019-03
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396707, "Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01396707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*